These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 16015594

  • 1. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
    Zhigang Z, Wenlu S.
    Prostate; 2005 Dec 01; 65(4):299-305. PubMed ID: 16015594
    [Abstract] [Full Text] [Related]

  • 2. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
    Zhigang Z, Wenlu S.
    Prostate; 2007 May 01; 67(6):653-60. PubMed ID: 17342746
    [Abstract] [Full Text] [Related]

  • 3. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
    Zhigang Z, Wenlv S.
    Jpn J Clin Oncol; 2004 Jul 01; 34(7):414-9. PubMed ID: 15342669
    [Abstract] [Full Text] [Related]

  • 4. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z, Liu J, Li S, Shen W.
    Prostate; 2009 Sep 01; 69(12):1292-302. PubMed ID: 19462463
    [Abstract] [Full Text] [Related]

  • 5. Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT.
    Iczkowski KA, Huang W, Mazzucchelli R, Pantazis CG, Stevens GR, Montironi R.
    Cancer; 2004 Jan 15; 100(2):294-9. PubMed ID: 14716763
    [Abstract] [Full Text] [Related]

  • 6. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
    Zhigang Z, Wenlu S.
    Prostate; 2008 Feb 01; 68(2):190-9. PubMed ID: 18076024
    [Abstract] [Full Text] [Related]

  • 7. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer.
    Zhigang Z, Wenlv S.
    World J Surg Oncol; 2004 May 10; 2():13. PubMed ID: 15132743
    [Abstract] [Full Text] [Related]

  • 8. Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer.
    Han KR, Seligson DB, Liu X, Horvath S, Shintaku PI, Thomas GV, Said JW, Reiter RE.
    J Urol; 2004 Mar 10; 171(3):1117-21. PubMed ID: 14767283
    [Abstract] [Full Text] [Related]

  • 9. Prostate stem cell antigen (PSCA) mRNA expression in prostatic intraepithelial neoplasia: implications for the development of prostate cancer.
    Zhigang Z, Wenlu S.
    Prostate; 2007 Aug 01; 67(11):1143-51. PubMed ID: 17503471
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z, Ma W, Zeng G, Qi D.
    J Surg Oncol; 2011 Nov 01; 104(6):672-8. PubMed ID: 21674503
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prostate stem cell antigen is overexpressed in prostate cancer metastases.
    Lam JS, Yamashiro J, Shintaku IP, Vessella RL, Jenkins RB, Horvath S, Said JW, Reiter RE.
    Clin Cancer Res; 2005 Apr 01; 11(7):2591-6. PubMed ID: 15814638
    [Abstract] [Full Text] [Related]

  • 14. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
    Lee CT, Capodieci P, Osman I, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C.
    Clin Cancer Res; 1999 May 01; 5(5):977-83. PubMed ID: 10353729
    [Abstract] [Full Text] [Related]

  • 15. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate.
    Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, Rangell L, Keller GA, Schow P, Steeves RM, Lutz RJ, Frantz G, Hillan K, Peale F, Tobin P, Eberhard D, Rubin MA, Lasky LA, Koeppen H.
    Cancer Res; 2002 May 01; 62(9):2546-53. PubMed ID: 11980648
    [Abstract] [Full Text] [Related]

  • 16. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
    Kameoka H, Katayose K, Kumakawa K, Shiraiwa Y, Uchida H, Takahashi Y, Yazaki J, Yamaguchi O.
    Gan To Kagaku Ryoho; 2005 Jan 01; 32(1):57-63. PubMed ID: 15675583
    [Abstract] [Full Text] [Related]

  • 17. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
    Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN.
    Br J Cancer; 2001 Dec 14; 85(12):1928-36. PubMed ID: 11747336
    [Abstract] [Full Text] [Related]

  • 18. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
    Janoff DM, Peterson C, Mongoue-Tchokote S, Peters L, Beer TM, Wersinger EM, Mori M, Garzotto M.
    BJU Int; 2005 Sep 14; 96(4):503-7. PubMed ID: 16104900
    [Abstract] [Full Text] [Related]

  • 19. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
    Sciarra A, Di Silverio F.
    Urology; 2004 Mar 14; 63(3):523-7. PubMed ID: 15028450
    [Abstract] [Full Text] [Related]

  • 20. In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.
    Festuccia C, Gravina GL, Muzi P, Pomante R, Ventura L, Ricevuto E, Vicentini C, Bologna M.
    Prostate; 2007 Sep 01; 67(12):1255-64. PubMed ID: 17596848
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.